Oncological Safety of Breast Conserving Surgery in Breast Cancer

Aleksandar Guzijan; Radoslav Gajanin; Jovan Ćulum; Zdenka Gojković; Ljubiša Preradović; Dragana Roganović

doi:10.5937/scriptamed53-38929

Aleksandar Guzijan University clinical center of the Republic of Srpska
Radoslav Gajanin Medicinski fakultet Univerziteta u Banjoj Luci
Jovan Ćulum Medicinski fakultet Univerziteta u Banjoj Luci
Zdenka Gojković Medicinski fakultet Univerziteta u Banjoj Luci
Ljubiša Preradović Arhitektonsko-građevinsko-geodetski fakultet Univerziteta u Banjoj Luci
Dragana Roganović Univerzitetski klinički centar Republike Srpske

DOI: https://doi.org/10.5937/scriptamed53-38929

Keywords: Breast cancer, Mastectomy, Breast-conserving surgery, Breast centre, Radiation therapy

Abstract

Background/Aim: Breast-conserving surgery is a type of surgery used as a treatment option for breast cancer. It was introduced at the end of the 20th century following and in accordance with relevant clinical studies. With heightened public awareness of breast cancer and the introduction of new diagnostic procedures, despite the proven oncological safety of this type of surgery, a growing number of women choose to undergo total mastectomy. The aim of this study was to confirm the oncological safety of breast-conserving surgery performed on breast cancer patients at the University Clinical Centre of the Republic of Srpska.

Methods: This study analysed 305 female patients with I and II stage of breast cancer, operated on between March 2009 and December 2013. One group of patients underwent breast-conserving surgery (BCS), followed by adjuvant radiation therapy and the other total mastectomy (MX). The patients were followed up for 5 years after the surgery. Analysed herein were the local-regional recurrence, distant metastases, disease-free survival and overall survival rates.

Results: After a five-year follow-up, the local-regional recurrence rate for patients in the BCS group was 4.3 %, while for the MX group it was 4.2 %. The overall survival rate of patients in the BCS group was 90.9 %, as opposed to 89.1 % for MX patients.

Conclusion: After a five-year follow-up, no statistically significant difference was observed between the two groups of patients regarding the local-regional recurrence (p = 0.967) and overall survival rates (p = 0.610). Breast-conserving surgery is an oncologically safe surgical treatment for breast cancer.

References

1. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347:123341.

Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002; 347(16):122732.

Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220:391-401.

Donker M, Van Tienhoven G, Straver ME, Meijnen P, Van de Velde CJ, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 2014;15:1303-10.

Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA 2017;318(10):918-26.

Broeders M, Moss S, Nystrom L, Njor S, Jonsson H, Paap E, et al. The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. J Med Screen 2012;19(Suppl 1):1425.

Punglia RS, Morrow M, Winer EP, Harris JR. Local therapy and survival in breast cancer. N Engl J Med 2007;356:2399405.

Solin LJ. Breast conservation treatment with radiation: an ongoing success story. J Clin Oncol 2010;28(5):70911.

Kummerow KL, Du L, Penson DF, Shyr Y, Hooks MA. Nationwide trends in mastectomy for early-stage breast cancer. JAMA Surg 2015;150(1):916.

Mamtani A, Morrow M. Why are there so many mastectomies in the United States? Ann Rev Med 2017;68:229-41.

Biganzoli L, Cardoso F, Beishon M, Cameron D, Cataliotti L, Coles CE, et al. The requirements of a specialist breast centre. Breast 2020;51:65–84.

Guzijan A, Babić B, Gojković Z, Gajanin R, Ćulum J, Grahovac D. Sentinel lymph node biopsy in breast cancer: Validation study and comparison of lymphatic mapping techniques. Scr Med 2014;45(2):56-61.

Jacobson JA, Danforth DN, Cowan KH, D’Angelo T, Steinberg SM, Pierce L, et al. Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med 1995;332(14):90711.

Arriagada R, Le MG, Guinebretiere JM, Dunant A, Rochard F, Tursz T. Late local recurrences in a randomised trial comparing conservative treatment with total mastectomy in early breast cancer patients. Ann Oncol 2003;14:161722.

Poggi MM, Danforth DN, Sciuto LC, Smith SL, Steinberg SM, Liewehr DJ, et al. Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: The National Cancer Institute randomized trial. Cancer 2003;98:697702.

Montagna G, Rittera M, Weber WP. News in surgery of patients with early breast cancer. Breast 2019;48(Suppl 1):S2–S6.

Morrow M, Harris JR, Schnitt SJ. Surgical margins in lumpectomy for breast cancer – Bigger is not better. N Engl J Med 2012;367(1):7982.

Plichta JK, Rai U, Tang R, Coopey SB, Buckley JM, Gadd MA, et al. Factors associated with recurrence rate and long-term survival in women diagnosed with breast cancer ages 40 and younger. Ann Surg Oncol 2016;23:3212-20.

Voogd AC, Nielsen M, Peterse JL, Blichert-Toft M, Bartelink H, Overgaard M, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large european randomized trials. J Clin Oncol 2001;19(6):1688-97.

Gnant M, Harbeck N, Thomssen C. Summary of the consensus discussion about escalation and de-escalation of primary breast cancer treatment. Breast Care 2017;12:1027.

Onitilo AA, Engel JM, Stankowski RV, Doi S. Survival comparisons for breast conserving surgery and mastectomy revisited: community experience and the role of radiation therapy. Clin Med Res 2015;13(2):6573.

Early breast cancer trialists’ collaborative group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet 2011;378:1707–16.

Christiansen P, Carstensen SL, Ejlertsen B, Kroman N, Offersen B, Bodilsen A, et al. Breast conserving surgery versus mastectomy: overall and relative survival - a population based study by the Danish Breast Cancer Cooperative Group (DBCG). Acta Oncol 2017;57(1):19-25.

Boniface J, Szulkin R, Johansson AL. Survival after breast conservation vs mastectomy adjusted for comorbidity and socioeconomic status: a Swedish national 6-year follow-up of 48 986 women. JAMA Surg 2021;156(7):628-37.